Results for tag: "Long Acting Muscarinic Antagonist"

The Long Acting Muscarinic Antagonist (LAMA) market is a subset of the larger respiratory drug market. LAMAs are used to treat chronic obstructive pulmonary disease (COPD) and asthma. These drugs work by blocking the action of acetylcholine, a neurotransmitter that causes airway constriction. This helps to reduce symptoms such as coughing, wheezing, and shortness of breath. LAMAs are typically administered via inhalation, and are available in both short-acting and long-acting formulations. Long-acting formulations provide sustained relief from symptoms over a longer period of time. Some of the major companies in the LAMA market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. These companies produce a variety of LAMA drugs, including tiotropium, aclidinium, umeclidinium, and glycopyrronium. Show Less Read more